Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer.
Saved in:
| Title: | Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer. |
|---|---|
| Authors: | Eisses B; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., van Geel JJL; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Brouwers AH; Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, the Netherland., Bensch F; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Elias SG; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Kuip EJM; Department of Medical Oncology, Radboud Medical Center, Nijmegen, The Netherlands., Jager A; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van der Vegt B; Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Lub-de Hooge MN; Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, the Netherland.; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Emmering J; Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands., Arens AIJ; Department of Radiology and Nuclear Medicine, Radboud Medical Center, Nijmegen, The Netherlands., Zwezerijnen GJC; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands., Vugts DJ; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands., Menke-van der Houven van Oordt CW; Department of Medical Oncology and Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; and., de Vries EGE; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Schröder CP; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; c.schroder@nki.nl.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. |
| Source: | Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2024 Oct 01; Vol. 65 (10), pp. 1540-1547. Date of Electronic Publication: 2024 Oct 01. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1535-5667 |
|---|---|
| DOI: | 10.2967/jnumed.124.267636 |
